Treatment of short bowel syndrome patients with colon-in-continuity

Abstract

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

What is claimed is: 
     
         1 . A method of treating an adult human patient having short bowel syndrome with at least 25% colon-in-continuity with remnant small intestine and who receives an amount of parenteral nutrition each week, said method comprising administering [Gly2]hGLP-2 to said patient using a dosing regimen effective to reduce or eliminate said weekly amount of parenteral nutrition received by said patient. 
     
     
         2 . The method as defined in  claim 1 , wherein said patient has at least 30% colon-in-continuity with remnant small intestine. 
     
     
         3 . The method as defined in  claim 2 , wherein said patient has at least 35% colon-in-continuity with remnant small intestine. 
     
     
         4 . The method as defined in  claim 3 , wherein said patient has at least 40% colon-in-continuity with remnant small intestine. 
     
     
         5 . The method as defined in  claim 4 , wherein said patient has at least 45% colon-in-continuity with remnant small intestine. 
     
     
         6 . The method as defined in  claim 5 , wherein said patient has at least 50% colon-in-continuity with remnant small intestine. 
     
     
         7 . The method as defined in  claim 6 , wherein said patient has at least 60% colon-in-continuity with remnant small intestine. 
     
     
         8 . The method as defined in  claim 7 , wherein said patient has at least 70% colon-in-continuity with remnant small intestine. 
     
     
         9 . The method as defined in  claim 8 , wherein said patient has at least 80% colon-in-continuity with remnant small intestine. 
     
     
         10 . The method as defined in  claim 9 , wherein said patient has at least 90% colon-in-continuity with remnant small intestine. 
     
     
         11 . The method as defined in  claim 1 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg. 
     
     
         12 . A method of treating an adult human patient having short bowel syndrome with at least 25% colon-in-continuity with remnant small intestine and who receives parenteral nutrition each week, said method comprising administering [Gly2]hGLP-2 to said patient using a dosing regimen effective to increase wet weight absorption compared to a baseline wet weight absorption by said patient. 
     
     
         13 . The method as defined in  claim 12 , wherein said patient has at least 30% colon-in-continuity with remnant small intestine. 
     
     
         14 . The method as defined in  claim 13 , wherein said patient has at least 35% colon-in-continuity with remnant small intestine. 
     
     
         15 . The method as defined in  claim 14 , wherein said patient has at least 40% colon-in-continuity with remnant small intestine. 
     
     
         16 . The method as defined in  claim 15 , wherein said patient has at least 45% colon-in-continuity with remnant small intestine. 
     
     
         17 . The method as defined in  claim 16 , wherein said patient has at least 50% colon-in-continuity with remnant small intestine. 
     
     
         18 . The method as defined in  claim 17 , wherein said patient has at least 60% colon-in-continuity with remnant small intestine. 
     
     
         19 . The method as defined in  claim 18 , wherein said patient has at least 70% colon-in-continuity with remnant small intestine. 
     
     
         20 . The method as defined in  claim 19 , wherein said patient has at least 80% colon-in-continuity with remnant small intestine. 
     
     
         21 . The method as defined in  claim 20 , wherein said patient has at least 90% colon-in-continuity with remnant small intestine. 
     
     
         22 . The method as defined in  claim 1 , wherein said regimen comprises administration of said [Gly2]hGLP-2 over a period of at least 21 days. 
     
     
         23 . The method as defined in  claim 12 , wherein said regimen comprises administration of said [Gly2]hGLP-2 over a period of at least 21 days. 
     
     
         24 . The method as defined in  claim 1 , wherein the parenteral nutrition is reduced by volume or frequency of administration. 
     
     
         25 . The method as defined in  claim 1  wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg by subcutaneous injection. 
     
     
         26 . The method as defined in  claim 12 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg by subcutaneous injection.